Calculation of dose distributions for 12 <sup>106</sup>Ru/<sup>106</sup>Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Hermida-López, M.

doi:10.1118/1.4820368

Cited by 25 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The determination of 3-D dose distributions is a current field of research [16,17,18,19,20,21,22,23,24]. This study is based on Monte Carlo simulated dose distributions of 3 eye plaque types.…”

Section: Introductionmentioning

confidence: 99%

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

et al. 2017

View full text Add to dashboard Cite

Brachytherapy with ¹⁰⁶Ru eye plaques is the most common treatment modality for small to medium-sized uveal melanomas in Europe. So far, no standardized or widely accepted dose prescription protocol for the irradiation of intraocular tumors with ¹⁰⁶Ru eye plaques has been defined. For ¹²⁵I plaques, the minimum dose required for tumor control should be at least 85 Gy. Concerning ¹⁰⁶Ru plaques, the dose prescriptions at the University Hospital of Essen foresees minimum doses of 700 Gy to the tumor base and 130 Gy to the tumor apex. These dose prescriptions are expected to ensure sufficient treatment margins. We apply these dose prescriptions to different eye plaque types and tumor sizes and discuss the resulting treatment margins. These investigations are based on Monte Carlo simulations of dose distributions of 3 different eye plaque types. The treatment margin in apical direction has an expansion of at least 0.8 mm for all investigated eye plaques. For symmetrically formed eye plaques, the treatment margin at the base of the tumor goes beyond the visible edge of the plaque. This study focuses on the shape of 85-Gy isodose lines and on treatment margins for different eye plaque types and tumor sizes and shall help exchange knowledge for ocular brachytherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

et al. 2017

View full text Add to dashboard Cite

show abstract

“…106 Rh nuclei, however, decay with a certain probability to excited states of 106 Pd, which in turn decay emitting gamma rays of discrete energy values . This 106 Rh gamma spectrum has been neglected in all published studies on Monte Carlo simulation of 106 Ru/ 106 Rh plaques, as it was considered that its influence on the absorbed dose distribution was negligible. This assumption is an approximation that was not justified quantitatively in any publication.…”

Section: Introductionmentioning

confidence: 99%

Technical Note: Monte Carlo study of¹⁰⁶Ru/¹⁰⁶Rh ophthalmic plaques including the¹⁰⁶Rh gamma spectrum

Hermida-López

Brualla

2017

Med. Phys.

View full text Add to dashboard Cite

show abstract

“…Therefore, the design of the ophthalmic plaques and selection of the radionuclide for intraocular cancers has been the primary goal of the clinical studies for many investigators 15 , 16 , 17 . Several investigations based on Monte Carlo simulations or experimental techniques have been performed for dosimetry of choroidal melanoma, using different ophthalmic plaques containing various brachytherapy sources 9 , 15 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 …”

Section: Introductionmentioning

confidence: 99%

Gold nanoparticle‐based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye

Asadi

Vaezzadeh

Masoudi

et al. 2015

J Applied Clin Med Phys

View full text Add to dashboard Cite

The effects of gold nanoparticles (GNPs) in 125I brachytherapy dose enhancement on choroidal melanoma are examined using the Monte Carlo simulation technique. Usually, Monte Carlo ophthalmic brachytherapy dosimetry is performed in a water phantom. However, here, the compositions of human eye have been considered instead of water. Both human eye and water phantoms have been simulated with MCNP5 code. These simulations were performed for a fully loaded 16 mm COMS eye plaque containing 13 125I seeds. The dose delivered to the tumor and normal tissues have been calculated in both phantoms with and without GNPs. Normally, the radiation therapy of cancer patients is designed to deliver a required dose to the tumor while sparing the surrounding normal tissues. However, as the normal and cancerous cells absorbed dose in an almost identical fashion, the normal tissue absorbed radiation dose during the treatment time. The use of GNPs in combination with radiotherapy in the treatment of tumor decreases the absorbed dose by normal tissues. The results indicate that the dose to the tumor in an eyeball implanted with COMS plaque increases with increasing GNPs concentration inside the target. Therefore, the required irradiation time for the tumors in the eye is decreased by adding the GNPs prior to treatment. As a result, the dose to normal tissues decreases when the irradiation time is reduced. Furthermore, a comparison between the simulated data in an eye phantom made of water and eye phantom made of human eye composition, in the presence of GNPs, shows the significance of utilizing the composition of eye in ophthalmic brachytherapy dosimetry Also, defining the eye composition instead of water leads to more accurate calculations of GNPs radiation effects in ophthalmic brachytherapy dosimetry.PACS number: 87.53.Jw, 87.85.Rs, 87.10.Rt

show abstract

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Cited by 25 publications

References 31 publications

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

Technical Note: Monte Carlo study of¹⁰⁶Ru/¹⁰⁶Rh ophthalmic plaques including the¹⁰⁶Rh gamma spectrum

Gold nanoparticle‐based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye

Contact Info

Product

Resources

About

Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Cited by 25 publications

References 31 publications

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques

Technical Note: Monte Carlo study of106Ru/106Rh ophthalmic plaques including the106Rh gamma spectrum

Gold nanoparticle‐based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye

Contact Info

Product

Resources

About

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Technical Note: Monte Carlo study of¹⁰⁶Ru/¹⁰⁶Rh ophthalmic plaques including the¹⁰⁶Rh gamma spectrum